| Literature DB >> 32734195 |
Qadeer Farhan1, Douglas Shemin1, Fizza S Gillani2, Erika M C D'Agata2.
Abstract
Entities:
Year: 2019 PMID: 32734195 PMCID: PMC7380341 DOI: 10.1016/j.xkme.2019.04.005
Source DB: PubMed Journal: Kidney Med ISSN: 2590-0595
Distribution of Pathogens Associated With Bloodstream Infections Among Hospitalized Maintenance Hemodialysis Patients
| Pathogen | Total Isolates | No. (% of all pathogens) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |||
| 252 (45.1%) | 29 (48.3%) | 37 (43.0%) | 49 (55.1%) | 32 (54.2%) | 30 (65.2%) | 17 (29.3%) | 24 (60.0%) | 21 (29.6%) | 13 (26.0%) | 0.002 | |
| Gram-negative bacteria | 149 (26.7%) | 15 (25.0%) | 19 (22.1%) | 15 (16.9%) | 14 (23.7%) | 9 (19.6%) | 24 (41.4%) | 9 (22.5%) | 25 (35.2%) | 19 (38.0%) | 0.003 |
| Coagulase-negative | 66 (11.8%) | 6 (10.0%) | 19 (22.1%) | 12 (13.5%) | 3 (5.1%) | 2 (4.3%) | 5 (8.6%) | 0 (0.0%) | 11 (15.5%) | 8 (16.0%) | 0.5 |
| 46 (8.2%) | 8 (13.3%) | 3 (3.5%) | 10 (11.2%) | 1 (1.7%) | 2 (4.4%) | 7 (12.1%) | 3 (7.5%) | 7 (9.9%) | 5 (10.0%) | 0.7 | |
| 30 (5.4%) | 1 (1.7%) | 3 (3.5%) | 1 (1.1%) | 8 (13.6%) | 2 (4.4%) | 4 (6.9%) | 4 (10.0%) | 3 (10.0%) | 4 (8.0%) | 0.08 | |
| Fungi | 16 (2.9%) | 1 (1.7%) | 5 (5.8%) | 2 (2.3%) | 1 (1.7%) | 1 (2.2%) | 1 (1.7%) | 0 (0.0%) | 4 (5.7%) | 1 (2.0%) | 0.9 |
| Total | 559 (100%) | 60 (100%) | 86 (100%) | 89 (100%) | 59 (100%) | 46 (100%) | 58 (100%) | 40 (100%) | 71 (100%) | 50 (100%) | 0.2 |
All were identified as Candida spp, except for 1 Cryptococcus sp in 2016.
Number and Percent of Pathogens That Tested Resistant to Selected Antimicrobials, Per Year of Study
| Pathogen, Antimicrobial | No. of Resistant Isolates/No. of Isolates Tested (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | ||
| Methicillin | 16/29 (55.2%) | 19/37 (51.4%) | 29/49 (59.2%) | 11/32 (34.4%) | 16/30 (53.3%) | 6/17 (35.3%) | 8/24 (33.3%) | 11/21 (52.4%) | 5/13 (38.5%) | 0.1 |
| Vancomycin | 4/8 (50.0%) | 2/3 (66.6%) | 3/10 (30.0%) | 0/1 (0.0%) | 1/2 (50.0%) | 3/7 (42.9%) | 0/3 (0.0%) | 1/7 (14.3%) | 2/5 (40%) | 0.2 |
| Gram-negative bacteria | ||||||||||
| Aminoglycosides | 0/15 (0.0%) | 0/17 (0.0%) | 3/15 (20.0%) | 6/14 (42.9%) | 1/9 (11.1%) | 4/23 (17.4%) | 0/9 (0.0%) | 3/22 (13.6%) | 3/17 (17.6%) | 0.4 |
| Extended-spectrum cephalosporins | 5/14 (35.7%) | 3/18 (16.7%) | 2/15 (13.3%) | 3/14 (21.4%) | 1/9 (11.1%) | 2/22 (9.1%) | 2/9 (22.2%) | 6/25 (24.0%) | 7/18 (38.9%) | 0.5 |
| Meropenem | 0/15 (0.0%) | 1/17 (5.9%) | 0/15 (0.0%) | 0/14 (0.0%) | 0/9 (0.0%) | 1/22 (4.5%) | 0/9 (0.0%) | 0/22 (0.0%) | 1/17 (5.9%) | 0.7 |
| Piperacillin/tazobactam | 2/14 (14.3%) | 3/18 (16.7%) | 0/13 (0.0%) | 3/13 (23.0%) | 0/9 (0.0%) | 3/21 (14.3%) | 1/8 (12.5%) | 1/25 (4.0%) | 2/18 (11.1%) | 0.4 |
| Fluoroquinolones | 3/15 (20.0%) | 1/18 (5.5%) | 3/15 (20.0%) | 8/14 (57.1%) | 1/9 (11.1%) | 5/23 (21.7%) | 1/9 (11.1%) | 5/25 (20.0%) | 3/19 (15.8%) | 0.9 |
| Multidrug resistant | 2/14 (14.3%) | 0/17 (0.0%) | 0/17 (0.0%) | 3/13 (23.1%) | 0/9 (0.0%) | 1/21 (4.8%) | 0/8 (0.0%) | 2/22 (9.1%) | 2/17 (11.8%) | 0.7 |
Tobramycin and/or gentamicin.
Cefepime, ceftazidime, and ceftriaxone.
Ciprofloxacin and levofloxacin.
Resistance to at least 1 antimicrobial in 3 or more antimicrobial categories, which included extended-spectrum cephalosporins, fluoroquinolones, aminoglycosides, meropenem (all organisms); and piperacillin/tazobactam (Enterobacteriaceae and Pseudomonas aeruginosa). Denominators represent number of isolates tested to all antimicrobials/classes.